Anixa Biosciences, Inc.

twitter logo
Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Breast Cancer Clinical Advisory Board
    • Cancer Business Advisory Board
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
      • Breast Cancer Clinical Advisory Board
  • Pipeline
  • Investors
    • Overview
    • News Releases
    • The Future of Cancer Immunotherapy & Women’s Health
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
    • YouTube Channel
  • Contact Us

SEC Filings

Investors

Investors

  • Overview
  • News Releases
  • The Future of Cancer Immunotherapy & Women’s Health
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Fact Sheet
    • Contact IR
    • RSS News Feed
  • SEC Filings

  • Overview
Filter Filings:
Date Form Description Docs XBRL Pages
03/27/18 424B5 Prospectus filed pursuant to Rule 424(b)(5) HTML PDF 35
03/09/18 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.2
EX-32.2
HTML PDF XBRL Viewer XLS XBRL Files 31
03/05/18 8-K Current report filing
Related Documents
EX-99.1
HTML PDF 4
02/15/18 CT ORDER Confidential treatment order PDF 1
02/15/18 SC 13D Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities HTML PDF 6
02/14/18 S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Related Documents
EX-5.1
EX-1
HTML PDF 37
02/12/18 DEF 14A Definitive proxy statements HTML PDF 36
01/30/18 SC 13G/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions HTML PDF 14
01/30/18 SC 13G/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions HTML PDF 14
01/26/18 PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition HTML PDF 36
RSS
  • << Previous
  • 1...
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • ...96
  • Next >>

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus
twitter logo

Latest News & Events

Feb 2, 2026

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

Read More...
Jan 27, 2026

Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Read More...
Dec 15, 2025

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

Read More...
Copyrights © 2026 Anixa Biosciences, Inc.. All Rights Reserved.
twitter logo Privacy Policy Terms of Use Disclaimer Sitemap